VKTX Stock Analysis: Viking Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.512m USD | 12M Return: 66.8% | US92686J1060 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 77.1M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Viking Therapeutics (NASDAQ: VKTX) is a San Diego-based, clinical-stage biopharmaceutical company founded in 2012 and listed on NASDAQ since April 2015, operating in the U.S. biotechnology sub-industry. Its pipeline is focused on metabolic and endocrine disorders, with no products yet approved or generating commercial revenue - a typical structure for a clinical-stage biotech, where value is driven primarily by pipeline progress, R&D spending, and access to capital markets.
The companys lead program, VK2809, is an oral, liver-targeted thyroid hormone receptor beta (TRß) selective agonist currently in a Phase IIb trial for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) - both large metabolic indications with significant unmet need. It also applies the same TRß mechanism (VK0214) to X-linked adrenoleukodystrophy, a rare neurodegenerative disorder. The broader pipeline includes VK5211, a selective androgen receptor modulator (SARM) in Phase II for muscle recovery following hip fracture surgery; VK0612 in Phase II for metabolic disorders and anemia; and VK2735, a dual glucagon-like peptide-1 (GLP-1) agonist in Phase 1, a mechanism class that has attracted substantial investor interest in the metabolic disease space.
- VK2735 obesity drug Phase 2 trial data readout
- Competition intensifies from Eli Lilly Zepbound and Novo Wegovy in GLP-1 market
- Strategic partnership or acquisition speculation supports premium valuation
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.80 > 0.02 and ΔFCF/TA -61.75 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.80 > 3% & CFO -418.4m > Net Income -534.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (115.9m) vs 12m ago 3.37% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -10.0k > 6 (EBIT TTM -560.0m / Interest Expense TTM 56.0k) |
| A: 0.78 (Total Current Assets 517.6m - Total Current Liabilities 109.7m) / Total Assets 521.9m |
| B: -2.17 (Retained Earnings -1.13b / Total Assets 521.9m) |
| C: -0.83 (EBIT TTM -560.0m / Avg Total Assets 674.9m) |
| D: 3.59 (Book Value of Equity 408.3m / Total Liabilities 113.6m) |
| Altman-Z'' = -3.76 = D |
As of September 24, 2026, the stock is trading at USD 41.65 with a total of 14,117,729 shares traded. Over the past week, the price has changed by +41.09%, over one month by +25.34%, over three months by +19.65% and over the past year by +66.80%.
Current recommended Stop Loss: 39.00 (which is 6.4% or 1.2 ATR below the current price).
Viking Therapeutics has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy VKTX.
- StrongBuy: 10
- Buy: 7
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 92.4 | 121.8% |
P/B = 8.2822
P/EG = -0.03
Revenue TTM = 0.0 USD
EBIT TTM = -560.0m USD
EBITDA TTM = -559.6m USD
Long Term Debt = 3.92m USD (estimated: total debt 4.09m - short term 161k)
Short Term Debt = 161k USD (from shortTermDebt, last quarter)
Debt = 4.09m USD (from shortLongTermDebtTotal, last quarter) (leases 4.09m already included)
Net Debt = -497.6m USD (calculated: Debt 4.09m - CCE 501.7m)
Enterprise Value = 3.01b USD (3.51b + Debt 4.09m - CCE 501.7m)
Interest Coverage Ratio = -10.0k (Ebit TTM -560.0m / Interest Expense TTM 56.0k)
EV/FCF = -7.20x (Enterprise Value 3.01b / FCF TTM -418.4m)
FCF Yield = -13.88% (FCF TTM -418.4m / Enterprise Value 3.01b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 431k) / Revenue TTM)
Tobins Q-Ratio = 5.78 (Enterprise Value 3.01b / Total Assets 521.9m)
Interest Expense / Debt = 1.37% (Interest Expense 56.0k / Debt 4.09m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -442.4m (EBIT -560.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.72 (Total Current Assets 517.6m / Total Current Liabilities 109.7m)
Debt / Equity = 0.01 (Debt 4.09m / totalStockholderEquity, last quarter 408.3m)
Debt / EBITDA = 0.89 (negative EBITDA) (Net Debt -497.6m / EBITDA -559.6m)
Debt / FCF = 1.19 (negative FCF - burning cash) (Net Debt -497.6m / FCF TTM -418.4m)
Total Stockholder Equity = 565.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -79.24% (Net Income -534.8m / Total Assets 521.9m)
RoE = -94.56% (Net Income TTM -534.8m / Total Stockholder Equity 565.6m)
RoCE = -98.33% (EBIT -560.0m / Capital Employed (Equity 565.6m + L.T.Debt 3.92m))
RoIC = -107.3% (out of range, set to none) (NOPAT -442.4m / Invested Capital 412.4m)
WACC = 12.56% (E(3.51b)/V(3.52b) * Re(12.57%) + D(4.09m)/V(3.52b) * Rd(1.37%) * (1-Tc(0.21)))
Discount Rate = 12.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.95 | Cagr: 5.18%
[DCF] Fair Price = unknown (Cash Flow -418.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.54 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.07 | Chg30d=+0.00% | Revisions=+17% | Analysts=16
EPS current Year (2026-12-31): EPS=-4.61 | Chg30d=+0.00% | Revisions=+11% | GrowthEPS=-44.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-4.32 | Chg30d=+0.00% | Revisions=+32% | GrowthEPS=+6.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +22% (up=29, down=18)